Glycerin, Lidocaine
Common brands: Abreva Rapid Pain Relief, Abreva, Tylenol Extra Strength, Vitamin D, Tylenol Regular Strength
Top reporter: Haleon Us Holdings Llc
Non-Standardized Chemical Allergen [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Provitamin D2 Compound [EPC]Expectorant [EPC]
13,890
Total Reports
1,329
Serious Reports
7
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.05%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Glycerin, Lidocaine.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DRUG INEFFECTIVE | 6,650 | |
| 2 | ORAL HERPES | 2,416 | |
| 3 | CONDITION AGGRAVATED | 1,895 | |
| 4 | DRUG ADMINISTRATION ERROR | 1,779 | |
| 5 | INCORRECT DRUG ADMINISTRATION DURATION | 803 | |
| 6 | HERPES SIMPLEX | 706 | |
| 7 | INCORRECT PRODUCT ADMINISTRATION DURATION | 611 | |
| 8 | LIP SWELLING | 540 | |
| 9 | WRONG TECHNIQUE IN PRODUCT USAGE PROCESS | 539 | |
| 10 | PRODUCT QUALITY ISSUE | 537 | |
| 11 | INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION | 491 | |
| 12 | APPLICATION SITE PAIN | 442 | |
| 13 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 388 | |
| 14 | PRODUCT COMPLAINT | 366 | |
| 15 | HYPERSENSITIVITY | 310 | |
| 16 | SWELLING FACE | 284 | |
| 17 | APPLICATION SITE ERYTHEMA | 245 | |
| 18 | APPLICATION SITE IRRITATION | 229 | |
| 19 | PRODUCT USE IN UNAPPROVED INDICATION | 215 | |
| 20 | APPLICATION SITE SWELLING | 208 | |
| 21 | PRODUCT USE ISSUE | 187 | |
| 22 | EXPIRED PRODUCT ADMINISTERED | 171 | |
| 23 | APPLICATION SITE SCAB | 165 | |
| 24 | ORAL DISCOMFORT | 153 | |
| 25 | INTENTIONAL DRUG MISUSE | 151 | |
| 26 | RASH | 150 | |
| 27 | CHEILITIS | 144 | |
| 28 | LIP PAIN | 144 | |
| 29 | PAIN | 125 | |
| 30 | LIP DRY | 124 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.